Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model

Critical Reviews in Oncology/Hematology

Volumn 102, Issue , 2016, Pages 101-110

  Strigari, Lidia ^a   Pinnarò, Paola ^a   Carlini, Paolo ^a   Torino, Francesco ^b   Strolin, Silvia ^a   Minosse, Silvia ^a   Sanguineti, Giuseppe ^a   Benassi, Marcello ^c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Advanced; Efficacy; Head and neck; Radiobiology; Toxicity; Tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DOSIMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MATHEMATICAL MODEL; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WART VIRUS; ADVERSE EFFECTS; BIOLOGICAL MODEL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; MUCOSA; RADIATION INJURY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MUCOUS MEMBRANE; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964908313     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.04.004     Document Type: Review

References (35)

1. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010, 363(1):24-35.
2. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.L., Greiner R.H., Giralt J., Maingon P., Rolland F., Bolla M., Cognetti F., Bourhis J., Kirkpatrick A., van Glabbeke M. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350(May (19)):1945-1952.
3. Blanchard P., Baujat B., Holostenco V., et al. Meta-analysis of chemotherapy in head and neck cancer (MAC H-NC): a comprehensive analysis by tumour site. Radiother. Oncol. 2011, 100(July (1)):33-40.
4. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11:21-28.
5. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368(9538):843-854.
6. Bourhis J., Sire C., Graff P., et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012, 13(2):145-153.
7. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 1998, 338(25):1798-1804.
8. Browman G.P., Hodson D.I., Mackenzie R.J., et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001, 23:579-589.
9. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J. Clin. Oncol. 2005, 23(6):1125-1135.
10. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 1998, 91:2081-2086.
11. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., Machtay M., Ensley J.F., Chao K.S., Schultz C.J., Lee N., Fu K.K. Radiation Therapy Oncology Group 9501/Intergroup: postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004, 350(May (9)):1937-1944.
12. Corvò R., Benasso M., Sanguineti G., et al. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer 2001, 92(11):2856-2867.
13. Dok R., Kalev P., Van Limbergen E.J., et al. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res. 2014, 74(6):1739-1751.
14. Fenwick J.D., Pardo-Montero J., Nahum A.E., et al. Impact of schedule duration on head and neck radiotherapy: accelerated tumor repopulation versus compensatory mucosal proliferation. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82(2):1021-1030.
15. Forastiere A.A., Zhang Q., Weber R.S., et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 2013, 31(7):845-852. Epub 2012 Nov 26. 10.1200/JCO.2012.43.6097.
16. Ghi M.G., Floriani I. Concomitant chemoradiation in locally advanced head and neck squamous cell chemotherapy carcinoma: a literature based meta-analysis on the platinum concomitant. J. Clin. Oncol. 2011, 29. 5534.
17. Go R.S., Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 1999, 409-422.
18. Hartley A., Sanghera P., Glaholm J., et al. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Clin. Oncol. (R. Coll. Radiol.) 2010, 22(2):125-130.
19. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J. Clin. Oncol. 2004, 22:4665-4673.
20. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother. Oncol. 1997, 43(1):29-37.
21. Jeremic B., Milicic B., Dagovic A., et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2004, 22(17):3540-3548.
22. Lamont E.B., Vokes E.E. Chemotherapy in the management of squamous cell carcinoma of the head and neck. Lancet Oncol. 2001, 2:261-269.
23. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22(April (4)):719-748.
24. Meade S., Sanghera P., McConkey C., et al. Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86(1):157-163.
25. Orrecchia R., Ragona R., Airoldi M., et al. Concomitant radiotherapy and daily low-dose carboplatin in locally advanced, unresectable head and neck cancer. Definitive results of a phase I-II study. Acta Oncol. 1994, 33(5):541-545.
26. Pajak T.F., Laramore G.E., Marcial V.A., et al. Elapsed treatment days: a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int. J. Radiat. Oncol. Biol. Phys. 1991, 20(1):13-20.
27. Pignon J.P., le Maitre A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MAC H-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 2009, 92:4-14.
28. Schaake-Konig C., Van der Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992, 326(8):524-530.
29. Schwachofer J.H., Croojimans R.P., Hoogenhout J., et al. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int. J. Radiat. Oncol. Biol. Phys. 1991, 20(6):1235-1241.
30. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50(5):1161-1171. Erratum in: Int. J. Radiat. Oncol. Biol. Phys. 2001; 51 (2): 569.
31. Strigari L., D'Andrea M., Abate A., Benassi M.A. Heterogeneous dose distribution in simultaneous integrated boost: the role of the clonogenic cell density on the tumor control probability. Phys. Med. Biol. 2008, 53(19):5257-5273. Epub 2008 Aug 29. 10.1088/0031-9155/53/19/001.
32. Strigari L., Pedicini P., D'Andrea M., Pinnarò P., Marucci L., Giordano C., Benassi M. A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83(5):e697-e702. Epub 2012 May 10. 10.1016/j.ijrobp.2012.02.004.
33. Worthington H.V., Clarkson J.E., Bryan G., et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev. 2011, CD000978.
34. Zackrisson B., Mercke C., Strander H., et al. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 2003, 42(5-6):443-461.
35. Zbaren P., Weidner S., Thoeny H.C. Laryngeal and hypopharyngeal carcinomas after (chemo)radiotherapy: a diagnostic dilemma. Curr. Opin. Otolaryngol. Head Neck Surg. 2008, 147-153.